Get the Stockscreener App
1.67
2.34%
-0.04
After Hours:
1.69
0.02
+1.20%
MAIA Biotechnology Inc stock is traded at $1.67, with a volume of 138.58K.
It is down -2.34% in the last 24 hours and down -10.70% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.71
Open:
$1.71
24h Volume:
138.58K
Relative Volume:
0.35
Market Cap:
$50.61M
Revenue:
-
Net Income/Loss:
$-25.94M
P/E Ratio:
-1.2101
EPS:
-1.38
Net Cash Flow:
$-15.79M
1W Performance:
-2.34%
1M Performance:
-10.70%
6M Performance:
-13.02%
1Y Performance:
-55.47%
1-Day Range:
$1.66
$1.72
1-Week Range:
$1.64
$1.90
52-Week Range:
$1.40
$4.24
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.67 | 52.62M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
Is MAIA Biotechnology Inc. a good long term investmentBreakthrough financial growth - jammulinksnews.com
What analysts say about MAIA Biotechnology Inc. stockGame-changing capital returns - jammulinksnews.com
MAIA Biotechnology Inc. Stock Analysis and ForecastExplosive capital gains - jammulinksnews.com
MAIA Biotechnology’s 41% decline validates InvestingPro’s overvalued call By Investing.com - Investing.com
What drives MAIA Biotechnology Inc. stock priceExceptional earning trajectories - Autocar Professional
Is MAIA Biotechnology Inc. stock a growth or value playMomentum Swing Watchlist - beatles.ru
When is the best time to buy MAIA Biotechnology Inc. stockPro Trader Stock Focus - Newser
Maia Biotechnology stock soars after publishing promising preclinical data - Investing.com
MAIA Biotechnology Publishes Promising Preclinical Cancer Data - TipRanks
MAIA Biotechnology publishes preclinical data on cancer drug candidates By Investing.com - Investing.com Canada
Maia Biotechnology stock soars after publishing promising preclinical data By Investing.com - Investing.com Canada
MAIA Biotechnology publishes preclinical data on cancer drug candidates - Investing.com
MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy - Business Wire
Why MAIA Biotechnology Inc. stock attracts strong analyst attentionFree Stock Selection - Newser
How MAIA Biotechnology Inc. stock performs during market volatilityFree Stock Investment Discussion Area - Newser
What makes MAIA Biotechnology Inc. stock price move sharplySteady Profit Stock Forecasts - Newser
MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial - Yahoo Finance
MAIA Biotechnology doses first patient in Taiwan for NSCLC trial By Investing.com - Investing.com South Africa
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer - BioSpace
MAIA Biotechnology Begins Phase 2 Trial Expansion - TipRanks
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Up 0.5% – Still a Buy? - Defense World
Public market insider buying at Canaccord Genuity Group (CF) - The Globe and Mail
MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress - BioSpace
Maia Biotechnology enters stock purchase agreement for up to $587,905 with Prevail Partners - Investing.com
MAIA Biotechnology, Roche Partner for Hard-to-Treat Cancer Therapies - Contract Pharma
MAIA Biotechnology appoints HCC experts to scientific advisory board - Investing.com
MAIA Biotechnology, Roche sign supply agreement for cancer therapies - Yahoo Finance
MAIA Biotechnology partners with Roche for cancer treatment studies By Investing.com - Investing.com South Africa
Maia Biotechnology Signs Clinical Supply Deal With Roche; Shares Rise - MarketScreener
MAIA Biotech (MAIA) Partners with Roche for Cancer Treatment Study - GuruFocus
MAIA Biotechnology, Inc. Announces Master Clinical Supply Agreement with Roche for Hard-To-Treat Cancer Therapies - marketscreener.com
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
Cap:
|
Volume (24h):